- Home
- VOR vs FATE Comparison
VOR vs FATE Comparison
Compare VOR & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- FATE
- Stock Information
- Founded
- VOR 2015
- FATE 2007
- Country
- VOR United States
- FATE United States
- Employees
- VOR N/A
- FATE N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VOR Health Care
- FATE Health Care
- Exchange
- VOR Nasdaq
- FATE Nasdaq
- Market Cap
- VOR 202.4M
- FATE 177.7M
- IPO Year
- VOR 2021
- FATE 2013
- Fundamental
- Price
- VOR $2.30
- FATE $1.14
- Analyst Decision
- VOR Buy
- FATE Hold
- Analyst Count
- VOR 7
- FATE 7
- Target Price
- VOR $3.77
- FATE $3.83
- AVG Volume (30 Days)
- VOR 47.3M
- FATE 1.6M
- Earning Date
- VOR 08-07-2025
- FATE 08-12-2025
- Dividend Yield
- VOR N/A
- FATE N/A
- EPS Growth
- VOR N/A
- FATE N/A
- EPS
- VOR N/A
- FATE N/A
- Revenue
- VOR N/A
- FATE $13,335,000.00
- Revenue This Year
- VOR N/A
- FATE N/A
- Revenue Next Year
- VOR N/A
- FATE N/A
- P/E Ratio
- VOR N/A
- FATE N/A
- Revenue Growth
- VOR N/A
- FATE 105.85
- 52 Week Low
- VOR $0.13
- FATE $0.66
- 52 Week High
- VOR $3.29
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- VOR 78.77
- FATE 46.98
- Support Level
- VOR $2.25
- FATE $1.12
- Resistance Level
- VOR $3.29
- FATE $1.18
- Average True Range (ATR)
- VOR 0.52
- FATE 0.07
- MACD
- VOR 0.18
- FATE 0.00
- Stochastic Oscillator
- VOR 82.52
- FATE 57.14
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.